Nava-Martín, D. (Daniel) de la

Filtering

2021 - 20222

Settings

Author search.filters.isAuthorOfPublication.9d3a254f-7e46-4632-8066-48e55de9acbd

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Immunovirotherapy for pediatric solid tumors: a promising treatment that is becoming a reality
    (2022) Mert-Selvi, K. (Kadir); Alonso-Roldán, M.M. (Marta María); Nava-Martín, D. (Daniel) de la
    Immunotherapy has seen tremendous strides in the last decade, acquiring a prominent position at the forefront of cancer treatment since it has been proven to be efficacious for a wide variety of tumors. Nevertheless, while immunotherapy has changed the paradigm of adult tumor treatment, this progress has not yet been translated to the pediatric solid tumor population. For this reason, alternative curative therapies are urgently needed for the most aggressive pediatric tumors. In recent years, oncolytic virotherapy has consolidated as a feasible strategy for cancer treatment, not only for its tumor-specific effects and safety profile but also for its capacity to trigger an antitumor immune response. This review will summarize the current status of immunovirotherapy to treat cancer, focusing on pediatric solid malignancies. We will revisit previous basic, translational, and clinical research and discuss advances in overcoming the existing barriers and limitations to translate this promising therapeutic as an every-day cancer treatment for the pediatric and young adult populations.
  • Thumbnail Image
    CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
    (2021) Ausejo-Mauleón, I. (Iker); Patiño-García, A. (Ana); Alonso-Roldán, M.M. (Marta María); Gomez-Manzano, C. (Candelaria); Zalacain, M. (Marta); Martinez-Velez, N. (Naiara); Gonzalez-Huarriz, M. (Marisol); Marrodán, L. (Lucía); Chen, Z. (ZhiHong); Garcia-Moure, M. (Marc); Hervas-Stubbs, S. (Sandra); Puigdelloses-Vallcorba, M. (Montserrat); Hambardzumyan, D. (Dolores); Labiano, S. (Sara); Laspidea, V. (Virginia); Fueyo, J. (Juan); Gallego-Perez-Larraya, J. (Jaime); Herrador-Cañete, G. (Guillermo); Jiang, H. (Hong); Nava-Martín, D. (Daniel) de la
    Background Glioblastoma (GBM) is a devastating primary brain tumor with a highly immunosuppressive tumor microenvironment, and treatment with oncolytic viruses (OVs) has emerged as a promising strategy for these tumors. Our group constructed a new OV named Delta-24-ACT, which was based on the Delta-24-RGD platform armed with 4-1BB ligand (4-1BBL). In this study, we evaluated the antitumor effect of Delta-24-ACT alone or in combination with an immune checkpoint inhibitor (ICI) in preclinical models of glioma. Methods The in vitro effect of Delta-24-ACT was characterized through analyses of its infectivity, replication and cytotoxicity by flow cytometry, immunofluorescence (IF) and MTS assays, respectively. The antitumor effect and therapeutic mechanism were evaluated in vivo using several immunocompetent murine glioma models. The tumor microenvironment was studied by flow cytometry, immunohistochemistry and IF. Results Delta-24-ACT was able to infect and exert a cytotoxic effect on murine and human glioma cell lines. Moreover, Delta-24-ACT expressed functional 4-1BBL that was able to costimulate T lymphocytes in vitro and in vivo. Delta-24-ACT elicited a more potent antitumor effect in GBM murine models than Delta-24-RGD, as demonstrated by significant increases in median survival and the percentage of long-term survivors. Furthermore, Delta-24-ACT modulated the tumor microenvironment, which led to lymphocyte infiltration and alteration of their immune phenotype, as ...